Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | BRD2 | P25440 | 1/20 | 0.49 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.49 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.49 |
| ▸ | PARN | O95453 | 1/20 | 0.49 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5789121 | 0.90 | KDM4E (0.55) | BRD4MEN1KMT2ACNOT7KDM4E | |
| SCHEMBL2957710 | 0.84 | ALDH1A1 (0.57) | MEN1KMT2ACNOT7POLBMAPK1 | |
| SCHEMBL6379875 | 0.82 | BRD4 (0.58) | BRD4MEN1KMT2ABRD2BRD3 | |
| SCHEMBL2967449 | 0.82 | PDE1A (0.62) | MEN1KMT2ACNOT7LMNAPOLB | |
| SCHEMBL5789117 | 0.81 | ALDH1A1 (0.51) | MEN1KMT2AKDM4EPOLBHPGD | |
| SCHEMBL556233 | 0.81 | BRD4 (0.82) | BRD4MEN1KMT2ABRD2BRD3 | |
| SCHEMBL5718879 | 0.80 | POLB (0.65) | MEN1KMT2ACNOT7LMNAPOLB | |
| SCHEMBL2961214 | 0.80 | POLB (0.64) | MEN1KMT2ACNOT7POLBMAPK1 | |
| SCHEMBL5719198 | 0.80 | BRD4 (0.64) | BRD4MEN1KMT2ABRD2BRD3 | |
| SCHEMBL556859 | 0.80 | BRD4 (0.63) | BRD4MEN1KMT2ABRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | EISAI CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20060100199-A1 | Novel condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060094722-A1 | Combination drug | EISAI CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060063787-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1557165-A1 | COMBINATION DRUG | Eisai Co., Ltd. (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-1514552-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | Eisai Co., Ltd. (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20040116328-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | MYT1, AQP4, AQP1 | BRD4 1982/4885MEN1 118/4885KMT2A 2285/4885 |
| US-20060100199-A1 | Novel condensed imidazole derivatives | H1-2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4 | BRD4 43/4885MEN1 164/4885KMT2A 926/4885 |
| US-20060094722-A1 | Combination drug | DPP4, GLP1R, DPP7 | BRD4 118/4885MEN1 1858/4885KMT2A 2689/4885 |
| US-20060063787-A1 | Condensed imidazole derivatives | DPP4, HDAC1, DPP7 | BRD4 48/4885MEN1 375/4885KMT2A 993/4885 |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | BRD4 48/4885MEN1 375/4885KMT2A 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.